If you have been reading about peptide research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-12. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The binding energy of the nucleus is the difference between the rest-mass energy of the nucleus and the rest-mass energy of the neutron and proton nucleons. The binding energy formula includes volume, surface and Coulomb energy terms that include empirically derived coefficients for all three, plus energy ratios of a deformed nucleus relative to a spherical form for the surface and Coulomb terms. Additional terms can be included such as symmetry, pairing, the finite range of the nuclear force, and charge distribution within the nuclei to improve the estimate. Normally binding energy is referred to and plotted as average binding energy per nucleon. According to Lilley, "The binding energy of a nucleus B is the energy required to separate it into its constituent neutrons and protons."
Giorgio Ortar et al. explored how the Stille-carbonylative cross-coupling could be used to synthesize benzophenone phosphores. These were embedded into 4-benzoyl-L-phenylalanine peptides and used for their photoaffinity labelling properties to explore various peptide-protein interactions.
The popularity of the game and its characters led Valve to develop merchandise for Portal made available through its online Valve physical merchandise store. Some of the more popular items were the Weighted Companion Cube plush toys and fuzzy dice. When first released, both were sold out in under 24 hours. Other products available through the Valve store include T-shirts and Aperture Science coffee mugs and parking stickers, and merchandise relating to the phrase "the cake is a lie", which has become an internet meme. Wolpaw noted they did not expect certain elements of the game to be as popular as they were, while other elements they had expected to become fads were ignored, such as a giant hoop that rolls on-screen during the final scene of the game that the team had named Hoopy. Swift stated that future Portal developments would depend on the community's reactions, saying, "We're still playing it by ear at this point, figuring out if we want to do multiplayer next, or Portal 2, or release map packs." Some rumors regarding a sequel arose due to casting calls for voice actors. On March 10, 2010, Portal 2 was officially announced for a release late in that year; the announcement was preceded by an alternate reality game based on unexpected patches made to Portal that contained cryptic messages in relation to Portal 2's announcement, including an update to the game, creating a different ending for the fate of Chell.
=== Hydrodynamic model === Transport through pores – in the simplest case – is done convectively. This requires the size of the pores to be smaller than the diameter of the two separate components. Membranes that function according to this principle are used mainly in micro- and ultrafiltration. They are used to separate macromolecules from solutions, colloids from a dispersion, or remove bacteria. During this process, the retained particles or molecules form a pulpy mass (filter cake) on the membrane, and this blockage of the membrane hampers the filtration. This blockage can be reduced by the use of the cross-flow method (cross-flow filtration). Here, the liquid to be filtered flows along the front of the membrane and is separated by the pressure difference between the front and back of the membrane into retentate (the flowing concentrate) on the front and permeate (filtrate) on the back. The tangential flow on the front creates a shear stress that cracks the filter cake and reduces the fouling.
Sources: en.wikipedia.org
=== Pilonidal sinus === Pilonidal sinus (PNS): a sinus tract, or small channel, that may originate from the source of infection and open to the surface of the skin. Material from the cyst drains through the pilonidal sinus. A pilonidal cyst is usually painful, but if it is a draining sinus, the pressure is relieved and the patient might not feel pain.
== Defrosting == To be used, many cooked foods that have been previously frozen require defrosting prior to consumption. Preferably, some frozen meats should be defrosted prior to cooking to achieve the best outcome: cooked through evenly and of good texture. The defrost system in freezers helps the equipment to perform properly, without thick layers of ice developing, thus preventing the evaporator coil from absorbing heat and cooling the cabinet. Ideally, most frozen foods should be defrosted in a refrigerator to avoid significant growth of pathogens. However, this can require considerable time. Food is often defrosted in one of several ways:
Freeman had four film releases in 1989. In the first, he starred as Sergeant Major John Rawlins in Glory, directed by Edward Zwick, about the 54th Massachusetts Infantry Regiment, the Union Army's second African-American regiment in the American Civil War. Writing for The Washington Post, Desson Thomson praised Freeman and co-star Denzel Washington for their "warming sense of fraternity". Glory was nominated for five Academy Awards and won three: Best Supporting Actor for Washington, Best Cinematography, and Best Sound. Next, Freeman starred in the comedy-drama Driving Miss Daisy, alongside Jessica Tandy and Dan Aykroyd. Based on Alfred Uhry's play of the same name in which Freeman had appeared previously, he reprises his role of Hoke Colburn, chauffeur for a Jewish widow. The film was a commercial success and grossed US$145 million worldwide. Film critics were mainly positive; Henry Sheehan from The Hollywood Reporter opined that Freeman and Tandy's performances complemented each other while retaining their "individual star-quality". The film was nominated for nine Academy Awards (and received four, Best Picture being one of them), including Best Actor for Freeman. His third release was the biographical drama Lean on Me, in which he portrays the principal of an under-performing and drug- and crime-ridden New Jersey high school. Jane Galbraith of Variety magazine thought Freeman's casting was "wonderful". Lastly in 1989, he starred in Walter Hill's Johnny Handsome, a crime drama in which he plays a New Orleans police officer.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.